Comparative efficacy and safety of oral P2Y 12 inhibitors after non-ST-elevation acute coronary syndromes: A network meta-analysis
Background Currently, potent P2Y 12 inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). The 2020 European Society of Cardiology (ESC) Guidelines recommend the use of prasugrel over ticagrelor in patients with non-ST-elevation ACS (N...
Main Authors: | Doundoulakis, I. (Author), Farmakis, I.T (Author), Giannakoulas, G. (Author), Karagiannidis, E. (Author), Karvounis, H. (Author), Kassimis, G. (Author), Michalis, L.K (Author), Moysidis, D.V (Author), Pagiantza, A. (Author), Stalikas, N. (Author), Zafeiropoulos, S. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
ST Segment Elevation Myocardial Infarction in Coronary Arteries with Massive Ectasy
by: Ana Rita G. Francisco, et al. -
Association of GRACE Risk Score with Coronary Artery Disease Complexity in Patients with Acute Coronary Syndrome
by: Georgios Sofidis, et al.
Published: (2021-05-01) -
Long-term results of different approaches to revascularization in non-ST-segment elevation acute coronary syndrome and multiple coronary atherosclerosis
by: V I Ganyukov, et al.
Published: (2017-04-01) -
Eosinophil count is related with coronary thrombus in non ST-elevated acute coronary syndrome
by: Erhan Tenekecioglu, et al.
Published: (2015-06-01) -
CLINICAL ASPECTS OF PATIENT SELECTION FOR CORONARY ANGIOGRAPHY IN NON-ST ELEVATION ACUTE CORONARY SYNDROME
by: K. A. Kireev
Published: (2015-09-01)